Introduction:
Venous malformations are the most common type of vascular malformations. Ethanol sclerotherapy is one of the most commonly used treatment methods. This study is to evaluate the initial results of digital subtraction angiography-guided ethanol sclerotherapy in patients with peripheral venous malformation.
Methods:
This was a retrospective cohort study of a single centre experience. Patients diagnosed with peripheral venous malformation who underwent digital subtraction angiography-guided ethanol sclerotherapy from Jan 2017 to Jun 2021 were included in the study. Medical records were reviewed to record demographic information, lesion characteristics including clinical and magnetic resonance imaging findings, treatment sessions, therapeutic outcomes, and complications.
Results:
A total of 104 patients were included. The mean number of procedures was 2.0 ± 1.3 times. Last follow-ups revealed a partial relief of symptoms in 97.2% of patients, and three patient (2.9%) showed no improvement. Post-treatment imaging revealed an overall objective response rate of 93.3%. Early post-procedural minor complications occurred after sclerotherapies in 31.7% of patients and were entirely resolved by conservative means. On multivariate analysis, poorly-defined margin (OR: 10.7, 95% CI: 2.28–76.9) and volume of venous malformation on MRI (OR: 1.04, 95% CI: 1.00–1.11) were independent predictors of “no-good response” to percutaneous ethanol sclerotherapy.
Conclusion:
Percutaneous sclerotherapy is safe and effective in the treatment of venous malformation. A poor-defined margin and volume of VMs on MRI were statistically significant predictors of the initial percutaneous ethanol sclerotherapy results and may be useful in selecting patients.
Highlights
Background
Thyroid cancer is the most common malignant disease in the endocrine glands. Symptoms of the disease affect the functions of organs in the body. Although thyroid cancer is often considered a “good cancer” because it progresses slowly, the likelihood of successful treatment is quite high; what is special is that the effect on the quality of life (QoL) is on par with more severe types of cancer. Currently, studies on QoL assessment in thyroid cancer patients are quite limited in southern Vietnam. The present study investigated the potential risk factors of deterioration in QoL scores in thyroid cancer patients after thyroidectomy.
Methodology
A descriptive, cross-sectional study was performed on a total of 162 patients who were diagnosed with thyroid cancer and underwent thyroidectomy at the University Medical Center Ho Chi Minh City, Vietnam, from February to May 2023. Data were collected through face-to-face interviews with patients and from medical records. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 was used to assess the QoL one month after thyroidectomy. Multivariable logistic regression was used to identify factors related to QoL with statistical significance set at p-value <0.05.
Results
The mean overall QoL in thyroid cancer survivors was 84.4 ± 10.00 (on a scale of 0-100, where 100 was the best). The results of multivariate logistic regression analysis showed that the factors related to QoL after thyroidectomy were surgery type (p < 0.001), having a comorbidity (p = 0.029), economic status (p = 0.026), and hormone disorder (p = 0.009).
Conclusions
Our study indicated that surgery type, having a comorbidity, economic status, and hormone disorders were independent risk factors for decreased QoL one month after thyroidectomy. It is necessary to thoroughly assess the QoL before and after surgery in thyroid cancer patients. Longer follow-up QoL studies should be performed with larger sample sizes for more accurate results.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.